Hemostemix (CVE:HEM) Shares Up 11.1%

Shares of Hemostemix Inc. (CVE:HEM) shot up 11.1% during mid-day trading on Friday . The stock traded as high as C$0.05 and last traded at C$0.05. 86,000 shares changed hands during mid-day trading, an increase of 37% from the average session volume of 62,705 shares. The stock had previously closed at C$0.05.

Hemostemix Stock Performance

The stock has a fifty day simple moving average of C$0.05 and a two-hundred day simple moving average of C$0.06. The stock has a market capitalization of C$4.36 million, a price-to-earnings ratio of -1.50 and a beta of 0.62.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.